Hurtado de Mendoza, Tatiana
Mose, Evangeline S.
Botta, Gregory P.
Braun, Gary B.
Kotamraju, Venkata R.
French, Randall P.
Suzuki, Kodai
Miyamura, Norio
Teesalu, Tambet
Ruoslahti, Erkki
Lowy, Andrew M.
Sugahara, Kazuki N. http://orcid.org/0000-0002-4946-192X
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R01CA167174)
Article History
Received: 21 February 2020
Accepted: 17 February 2021
First Online: 9 March 2021
Competing interests
: K.N.S., V.R.K., T.T., and E.R. have ownership interest (including patents) in Cend Therapeutics Inc. K.N.S., T.T., and E.R. are also co-founders and stockholders of Cend Therapeutics Inc. E.R. is the chairman of the board of Cend Therapeutics Inc. No potential conflicts of interest were disclosed by the other authors.